NCT03932526: Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer

NCT03932526
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: HER2-low
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Chemotherapy, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 70 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with untreated symptomatic brain metastasis that require treatment- see trial for details
https://ClinicalTrials.gov/show/NCT03932526

Comments are closed.

Up ↑